BioSpace News Archive

- The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date November 3, 2020 Time 11:30 AM (EST) Location Sir John A Macdonald Building, Room 200 144 Wellington Street, Ottawa, Ontario The media availability will also be he

- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced today the appointment of Charles J. Fisher, Jr. , M.D., as Chief Executive Officer, effective as of October 30 , 2020. Dr. Fisher joined Aethlon as a member of Aethlon’

Bioceres Crop Solutions Corp. (“Bioceres”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, today announced that it plans to release its Fiscal First Quarter 2021 financial and operating results on Thursday, November 12, 2020 before the market open of the New York Stock Exchange

Advanced Sterilization Products Unveils New-and-Improved STERRAD ® Sterility Guide (SSG) for Infection Prevention Professionals Online resource of reliable up-to-date STERRAD ® Systems sterilization information Both ASP and device manufacturers jointly perform a series of validations before a device can be added to the SSG, which is reassessed yearly to ensure quality and trust IRVINE, Calif.--( BUSINESS WIRE )-- Advanced Steriliza

Apollo Endosurgery, Inc. today announced that its management team will participate in two upcoming investor conference events during November 2020. November 17, 2020

Research agreement to investigate the feasibility of a proprietary biotechnology process for the industrial production of psilocybin API Psilocybin is designated by the FDA as a breakthrough therapy for severe depression

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that its mass cytometry technologies, including CyTOF ® , Imaging Mass Cytometry (IMC), and Maxpar ® Direct™, have been used in 113 National Clinical Trials listed in the clinicaltrials.gov database. This includes 94 ongoing and 19 completed clinical trials. Twenty-five

Full enrollment of 195 subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021

Abcam plc announces that, following consultation with shareholders on the Group’s overall LTIP structure and performance framework, including proposed changes for this year’s awards, it has determined to retain the existing LTIP metrics and targets contained in Abcam’s current Remuneration Policy, as approved by shareholders in 2018.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020 after th